Immunotherapy and targeted therapies in melanoma at ASCO 2015 At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews the results of the phase 3 CheckMate 067 trial of nivolumab in treatment-naive patients with advanced melanoma, and the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive melanoma.